Daniel A. Carestio
President & Chief Executive Officer at STERIS
Thanks Mike, and good morning everyone. Thank you for taking the time to join us to hear more about our third quarter performance and our outlook for the rest of the fiscal year. As you heard from Mike, our third quarter continued the momentum we have experienced in our healthcare segment the past few quarters, and we also saw nice improvement in Life Sciences. Overall, we are pleased with our performance. We continue to expect that our Healthcare segment will outperform our original expectations for the fiscal year, offsetting macro challenges impacting demand in our other segments.
Looking at our segments, Healthcare constant currency organic revenue grew 12% in the quarter, supporting that performance, we had double digit growth across capital equipment, consumables and service again this quarter. This is driven primarily by procedure volume rebound in the US, as well as price and market share gains.
As anticipated, backlog continues to normalize as we are shipping at a faster pace than new orders are coming in. Remember, our goal is to get back to historic production lead times and continue to meet customer demand. Speaking of demand, capital equipment orders in the Healthcare segment grew double digits in the quarter.
Turning to AST, constant currency organic revenue grew 4% which was below our expectations. While we have continued to see more normalized volumes in the US for medtech, outside of the US remains softer than anticipated. In addition, bioprocessing volumes continued to contract. Until we have more clarity, we are taking a more conservative approach to our expectations for the fourth quarter.
Life Sciences grew 20% in the quarter on a constant currency organic basis. We had another strong quarter of capital shipments which grew 57% against relatively easy comparisons. Remember, in fiscal 2023, revenue for both capital equipment and consumables was shifted from the third quarter to the fourth quarter due to some supply chain constraints. Consumables grew 8% and service revenue increased 12%. As you're hearing from others in the space, short-term demand remains a bit murky and we continue to be optimistic about the long-term growth opportunities for this segment.
Our Dental segment third quarter revenue declined 6% on a constant currency organic basis. Revenue was limited by reduced orders from a large customers due to a temporary disruption of their operations as a result of a cybersecurity incident they experienced during the quarter. Excluding that disruption, revenue would have been about flat in the quarter, which reflects the decline in patient volumes. The lower volume, combined with the continued increases in material costs led to a decline in EBIT margin for the quarter.
Turning to our outlook, fiscal 2024 is shaping up to be another strong year for STERIS, albeit not exactly the way we had anticipated. In the last few years, if they've taught us anything, it's the value of our diversified portfolio. Time and time again, we have benefited as one of our segments outperforms to compensate for challenges elsewhere. We are updating our outlook for the year to increase revenue to reflect the continued outperformance of our Healthcare segment.
For the year, we now expect total revenue to grow 10% to 11% on a constant currency organic basis. I'm sorry, in constant currency organic revenue growth of 7% to 8%, each up 100 basis points from our prior ranges. This assumes low single digit constant currency organic revenue growth in the fourth quarter caused by the record setting shipments in last year's fourth quarter.
EBIT margins for the fiscal year will decline slightly from fiscal 2023, primarily reflecting the shift in operating income mix from AST to Healthcare. Adjusted earnings per diluted share are now anticipated to be in the range of $8.60 to $8.70 for fiscal 2024. We recognize this outlook includes some conservatism, but believe it is warranted until we see the AST customer destocking abate and have additional clarity on bioprocessing volumes.
That concludes our prepared remarks for the call. Julie, would you please give the instructions and we can begin the Q&A.